The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care

The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care

Abstract Background The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effectiveness, safety and healthcare utilization of empa...

Full description

Bibliographic Details
Main Authors: Elisabetta Patorno, Mehdi Najafzadeh, Ajinkya Pawar, Jessica M. Franklin, Anouk Déruaz‐Luyet, Kimberly G. Brodovicz, Adrian J. Santiago Ortiz, Lily G. Bessette, Martin Kulldorff, Sebastian Schneeweiss
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
comparative effectiveness
confounding (epidemiology)
empagliflozin
heart failure
real‐world data
study validity
Online Access:https://doi.org/10.1002/edm2.103

Internet

https://doi.org/10.1002/edm2.103

Similar Items